The Safety and Efficacy of New Drug Approval.¶
Gieringer, D. H. (1985). The Safety and Efficacy of New Drug Approval. Cato Journal, 5(1), 177-201.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Omission Bias
- In policy and regulation it is the asymmetric scrutiny of errors of commission (a drug approved that causes harm) over errors of omission (a beneficial drug delayed or denied, whose victims are statistical and unattributed), biasing regulators toward inaction.
This sourceDocuments the FDA's asymmetric incentive to avoid errors of commission (approving a harmful drug, with visible victims) over errors of omission (delaying or denying a beneficial drug, whose victims are statistical and unattributed), biasing the agency toward inaction.
- In policy and regulation it is the asymmetric scrutiny of errors of commission (a drug approved that causes harm) over errors of omission (a beneficial drug delayed or denied, whose victims are statistical and unattributed), biasing regulators toward inaction.
Verification¶
Does it exist? Not checked yet. This entry carries no identifier to resolve. It was extracted from the citation as written in the article, normalized, and deduplicated against the rest of the registry.
Does it back the claim? Not recorded. The single citation of this work carries no recorded support check.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:5f3b2ee3a213 · see in the full table